Back to Search Start Over

Targeted temperature management for 48 vs 24 hours and neurologic outcome after out-of-hospital cardiac arrest: A randomized clinical trial

Authors :
Kirkegaard, Hans
Sørensen, Christina Ankjær
Ilkjær, Susanne
Jeppesen, Anni Nørregaard
Grejs, Anders
Duez, Christophe Henri Valdemar
Hjort, Jakob
Larsen, Alf Inge
Toome, Valdo
Tiainen, Marjaana
Hästbacka, Johanna
Søreide, Eldar
Laitio, Timo
Skrifvars, Markus M.B.
de Haas, Inge
Pettila, Ville
Taccone, Fabio
Arus, Urmet
Storm, Christian
Hassager, Christian
Nielsen, Jørgen Feldbæk
Kirkegaard, Hans
Sørensen, Christina Ankjær
Ilkjær, Susanne
Jeppesen, Anni Nørregaard
Grejs, Anders
Duez, Christophe Henri Valdemar
Hjort, Jakob
Larsen, Alf Inge
Toome, Valdo
Tiainen, Marjaana
Hästbacka, Johanna
Søreide, Eldar
Laitio, Timo
Skrifvars, Markus M.B.
de Haas, Inge
Pettila, Ville
Taccone, Fabio
Arus, Urmet
Storm, Christian
Hassager, Christian
Nielsen, Jørgen Feldbæk
Source :
JAMA (Chicago, Ill.), 318 (4
Publication Year :
2017

Abstract

IMPORTANCE: International resuscitation guidelines recommend targeted temperature management (TTM) at 33°C to 36°C in unconscious patients with out-of-hospital cardiac arrest for at least 24 hours, but the optimal duration of TTM is uncertain. OBJECTIVE: To determine whether TTM at 33°C for 48 hours results in better neurologic outcomes compared with currently recommended, standard, 24-hour TTM. DESIGN, SETTING, AND PARTICIPANTS: This was an international, investigator-initiated, blinded-outcome-assessor, parallel, pragmatic, multicenter, randomized clinical superiority trial in 10 intensive care units (ICUs) at 10 university hospitals in 6 European countries. Three hundred fifty-five adult, unconscious patients with out-of-hospital cardiac arrest were enrolled from February 16, 2013, to June 1, 2016, with final follow-up on December 27, 2016. INTERVENTIONS: Patients were randomized to TTM (33 ± 1°C) for 48 hours (n = 176) or 24 hours (n = 179), followed by gradual rewarming of 0.5°C per hour until reaching 37°C. MAIN OUTCOMES AND MEASURES: The primary outcome was 6-month neurologic outcome, with a Cerebral Performance Categories (CPC) score of 1 or 2 used to define favorable outcome. Secondary outcomes included 6-month mortality, including time to death, the occurrence of adverse events, and intensive care unit resource use. RESULTS: In 355 patients who were randomized (mean age, 60 years; 295 [83%] men), 351 (99%) completed the trial. More patients in the 48-hour group had a favorable outcome, but this was not statistically significant. Six-month mortality was not different between the groups. Adverse events were more common in the 48-hour group than in the 24-hour group. There was no significant difference in the time to mortality (hazard ratio, 0.79; 95% CI, 0.54-1.15; P = .22). The median length of ICU stay (151 vs 117 hours; P < .001), but not hospital stay (11 vs 12 days; P = .50), was longer in the 48-hour group than in the 24-hour group. (Table Presented) C<br />SCOPUS: ar.j<br />info:eu-repo/semantics/published

Details

Database :
OAIster
Journal :
JAMA (Chicago, Ill.), 318 (4
Notes :
1 full-text file(s): application/pdf, English
Publication Type :
Electronic Resource
Accession number :
edsoai.on1012854409
Document Type :
Electronic Resource